Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817791 | 0.84 | POLB (0.61) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL7500028 | 0.82 | POLB (0.52) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL30876406 | 0.82 | POLB (0.49) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL19317381 | 0.82 | POLB (0.49) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL29075996 | 0.81 | POLB (0.69) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL7503707 | 0.81 | POLB (0.48) | POLBLMNATSHRSMN1; SMN2GAA | |
| Lithium Ion SCHEMBL5868305 | 0.80 | POLB (0.47) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL20025128 | 0.80 | POLB (0.47) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL4840210 | 0.79 | POLB (0.46) | POLBLMNATSHRSMN1; SMN2GAA | |
| SCHEMBL30676280 | 0.78 | POLB (0.46) | POLBLMNATSHRSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | POLB 4857/4885LMNA 3469/4885TSHR 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.